Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05678218
Other study ID # MEC-2022-0402
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 5, 2022
Est. completion date February 1, 2026

Study information

Verified date April 2024
Source Erasmus Medical Center
Contact David de Jong, BSc
Phone 010 704 0704
Email d.m.dejong@erasmusmc.nl
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The goal of this observational cohort study is to assess the yield of preoperative endoscopic ultrasound focussed on lymph nodes in patients with presumed resectable perihilar (pCCA), intrahepatic (iCCA) or mid-common bile duct (CBD) cholangiocarcinoma. The main questions it aims to answer is: 1. The number of patients precluded from surgical work-up due to positive regional or extraregional lymph nodes identified by endoscopic ultrasound guided tissue acquisition 2. Characteristics during endoscopic ultrasound of lymph nodes associated with malignancy


Read more »

Study Design


Intervention

Procedure:
Endoscopic Ultrasound registration
Registration of all findings during Endoscopic Ultrasound

Locations

Country Name City State
Belgium University Hospital of Ghent Ghent
Netherlands Amsterdam University Medical Center Amsterdam Noord-Holland
Netherlands University Medical Center Groningen Groningen
Netherlands Leiden University Medical Center Leiden Zuid-Holland
Netherlands Maastricht UMC+ Maastricht Limburg
Netherlands Erasmus University Medical Center Rotterdam Zuid-Holland
Netherlands University Medical Center Utrecht Utrecht

Sponsors (1)

Lead Sponsor Collaborator
Erasmus Medical Center

Countries where clinical trial is conducted

Belgium,  Netherlands, 

References & Publications (5)

See more »

Outcome

Type Measure Description Time frame Safety issue
Primary Lymph nodes identified compared to imaging Number of lymph nodes correctly identified based on visualization and biopsy in comparison to cross-sectional imaging Through study completion, max 1 year
Primary Lymph nodes identified compared to surgery Number of lymph nodes correctly identified based on visualization and biopsy in comparison to surgery, in the patients in which this is performed Through study completion, max 1 year
Secondary Endoscopic Ultrasound (EUS)-characteristics predictive for malignant involvement of lymph nodes Rate of malignant lymph nodes in which a certain characteristic is present (f.e. shape of the lymph node), in comparison to benign lymph nodes. Through study completion, max 1 year
Secondary Different locations of positive lymph nodes and its effect on survival Days of survival after EUS and surgery, stratified per cholangiocarcinoma type, as well as lymph node locations Through study completion, max 1 year
Secondary Short term and long term complications of the EUS (+/- tissue acquisition) procedure for patients with pCCA and iCCA Short term (<30 days)
Sedation related: consisting of cardiovascular-related complications (cardiac arrhythmias, myocardial ischemia/infarction), respiratory- related complications (respiratory depression, hypoxia, airway obstruction, pulmonary aspiration of gastric contents) and allergic reactions.
Hemorrhage (outside peritoneal wall): defined as clinical evidence of bleeding with a hemoglobin drop of >3g/dl with the need for resuscitation or additional intervention
Perforation: defined as evidence of air or luminal contents outside the gastro-intestinal tract together with clinical symptoms, requiring percutaneous drainage or surgery
Mortality
Long term (>30 days)
- Tumor seeding; defined as proof of carcinoma in the biopsy tract during follow-up or at autopsy
Through study completion, max 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05179486 - Molecular Epidemiology of Biliary Tree Cancers
Suspended NCT05124743 - HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
Terminated NCT04304781 - Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer Phase 1
Completed NCT03150615 - Enteral Nutrition After Pancreaticoduodenectomy N/A
Completed NCT01912053 - Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma Phase 2
Recruiting NCT01439698 - Radio Frequency Ablation in the Management of Pancreatico-biliary Disorders: A Multicenter Registry N/A
Terminated NCT01434459 - Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin Phase 1
Completed NCT01206049 - Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations Phase 2
Recruiting NCT00973713 - Study of RAD001 in Advanced Cholangiocarcinoma: RADiChol Phase 2
Terminated NCT00975039 - Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma Phase 2
Completed NCT00779454 - Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma Phase 2
Terminated NCT04066491 - Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC Phase 2/Phase 3
Recruiting NCT04340986 - Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma
Active, not recruiting NCT04526106 - REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03603834 - Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma Phase 2
Recruiting NCT05007106 - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) Phase 2
Terminated NCT04077372 - Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers N/A